Press Room

Press Room

  • May 6, 2019
    Business Worldwide Magazine Spring 2019 issue: Alex Zwyer - Co-founder and CEO of NLS Pharmaceutics Ltd. (NLS) - explains the discovery and benefits of his organisation’s revolutionary medication.

    READ ARTICLE

  • Feb 21, 2019
    ADHD and its medications: An Illustrated History Over Time, by Eric Konofal MD, PhD. It is the first book totally devoted to the history of ADHD, encompassing the literary, philosophical, medical, neuropsychological and therapeutical aspects of attention, hyperactivity and ADHD, with more than 400 illustrations and 500 bibliographic references

    VIEW BOOK DESCRIPTION   BUY ON AMAZON

  • Jul 1st, 2018
    InsightSuccess featuring NLS’ CEO

    VIEW INTERVIEW

  • Aug 22, 2018
    NLS-1 Pharma’s CEO Alex Zwyer interview at Business Worldwide Magazine

    VIEW INTERVIEW

  • Jul 20, 2018
    NLS-1 Pharma’s CEO Alex Zwyer interviewed at The London Stock Exchange Studios

    WATCH FULL INTERVIEW

  • May, 2018
    New Era in the ADHD Space

    READ THE NEWS

  • Mar, 2018
    A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

    READ THE NEWS

  • June, 2017
    NLS-1 touts Mazindol's efficacy as it takes on ADHD market

    READ THE NEWS

  • June, 2017
    NLS-1 phase II results advance effort to carve out alternative ADHD drug niche

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 touts positive ADHD data, plots late-stage tests

    READ THE NEWS

  • June, 2017
    Potential Treatment for ADHD Yields Positive Phase II Data

    READ THE NEWS

  • June, 2017
    NLS-1 Pharma’s new ADHD compound could break the focus of the field

    READ THE NEWS

  • June, 2017
    The Handoff: Your Week in Neurology News

    READ THE NEWS

  • June, 2017
    Is ADHD a sleep disorder? Stimulant drug improves symptoms

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    NLS-1 Pharma Pins Hopes On Ex-Obesity Drug For ADHD

    READ THE NEWS

  • June, 2017
    Mid-stage data show promise for mazindol C-R

    READ THE NEWS

  • June, 2017
    NLS-1 Pharma’s results offer hope of changing ADHD landscape

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS